Key facts for DRG 821
- FY2027 relative weight
- 2.2023
- Higher than 68% of all MS-DRGs
- Change vs FY2026
- -1.6%
- FY2026 weight 2.2386
- Geometric mean LOS
- 3.1 days
- Arithmetic mean 4.9 days
- MDC
- 17
- Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
- Severity level
- with CC (complication or comorbidity)
- National unadjusted operating payment
- $15,081.35
- Weight × $6,848.00 FY2027 standardized amount; capital adds $1,189.13
- Transfer policy
- Not a transfer DRG
TL;DR
MS-DRG 821 is a surgical group in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms), at the middle of three severity levels in its CC/MCC family. CMS assigns it a FY2027 relative weight of 2.2023 with a geometric mean length of stay of 3.1 days and an arithmetic mean of 4.9. Its weight moved down 1.6% from FY2026 (2.2386). That weight is higher than 68% of all MS-DRGs. Its weight sits 64.8% below DRG 820 (with MCC, 6.2481) and 95.4% above DRG 822 (without CC/MCC, 1.1272). The v44 Definitions Manual assigns it through 552 principal diagnosis codes and 4,536 operating room procedures codes.
What changed from FY2026 to FY2027
CMS recalibrates every MS-DRG weight annually from the prior year's MedPAR claims. For DRG 821 the FY2027 relative weight is 2.2023 against 2.2386 in FY2026, a fall of 1.62%.
| Metric | FY2026 | FY2027 | Change |
|---|---|---|---|
| Relative weight | 2.2386 | 2.2023 | -0.0363 |
| Geometric mean LOS (days) | 3.3 | 3.1 | -0.2 |
| Arithmetic mean LOS (days) | 5.2 | 4.9 | -0.3 |
CC and MCC family
DRG 821 shares its base definition with 2 other MS-DRGs split by severity. The family's weights span 1.1272 to 6.2481, a 5.54× spread, which is the payment effect of documenting qualifying complications and comorbidities.
| DRG | Title | FY2027 weight | GMLOS | National operating payment |
|---|---|---|---|---|
| 820 | Lymphoma and Leukemia with Major O.R. Procedures with MCC | 6.2481 | 11.2 | $42,786.99 |
| 821 | Lymphoma and Leukemia with Major O.R. Procedures with CC | 2.2023 | 3.1 | $15,081.35 |
| 822 | Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC | 1.1272 | 1.4 | $7,719.07 |
At the national rate, documenting the family's top severity level (DRG 820, $42,786.99) instead of its base level (DRG 822, $7,719.07) changes the operating payment by $35,067.92. The figures are national operating amounts before the hospital-specific adjustments described below.
National unadjusted payment for DRG 821
Multiplying the FY2027 relative weight (2.2023) by the national rates in IPPS Tables 1A and 1D, as corrected by notice CMS-1849-CN3, gives the base amounts below. Across the CC/MCC family the operating amount spans $35,067.92.
| Component | National rate | DRG 821 |
|---|---|---|
| Operating (labor and nonlabor share) | $4,519.68 + $2,328.32 = $6,848.00 | $15,081.35 |
| Capital (federal rate) | $539.95 | $1,189.13 |
| Operating plus capital | $16,270.48 |
These are national, unadjusted figures, not what a given hospital is paid. The labor share is multiplied by the hospital's wage index (Table 1A applies when the wage index is above 1.0 and Table 1B otherwise), and teaching (IME), disproportionate share (DSH), outlier, transfer and new-technology add-on rules then change the amount for each stay. Use the figures to compare groups and to size a documentation finding, not to forecast a remittance; the DRG payment calculator applies a hospital's own wage index and teaching and DSH factors to DRG 821.
Risk-adjusting diagnoses in this DRG
Appendix B of the v44 Definitions Manual lists 552 ICD-10-CM codes in the logic for DRG 821; 548 of them also map to a CMS-HCC V28 payment category, across 8 categories. The same documentation that supports the inpatient group feeds Medicare Advantage risk adjustment when the patient is an MA enrollee.
| V28 HCC | Category | Shared codes | Examples |
|---|---|---|---|
| HCC 21 | Lymphoma and Other Cancers | 278 | C46.3, C81.00, C81.01 |
| HCC 20 | Lung and Other Severe Cancers | 139 | C77.3, C83.10, C83.11 |
| HCC 19 | Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers | 52 | C84.40, C84.41, C84.42 |
| HCC 17 | Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic | 41 | C77.1, C77.8, C7B.01 |
| HCC 22 | Bladder, Colorectal, and Other Cancers | 25 | C26.1, C91.10, C91.11 |
| HCC 18 | Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid | 11 | C77.0, C77.2, C77.4 |
| HCC 23 | Prostate, Breast, and Other Cancers and Tumors | 1 | D45 |
| HCC 109 | Acquired Hemolytic, Aplastic, and Sideroblastic Anemias | 1 | D61.82 |
New for FY2027: codes that group to DRG 821
IPPS Tables 6A and 6B assign 5 new ICD-10-PCS codes to DRG 821 from October 1, 2026. Encoders and edit tables that still run the v43 code set reject these codes or group them elsewhere, so check them first when a FY2027 discharge in this DRG fails an edit. The FY2027 ICD-10 code-change report lists every addition and deletion with its CC level and MS-DRGs.
| ICD-10-PCS | Description | O.R. | Effective |
|---|---|---|---|
| 0DDU0ZZ | Extraction of Omentum, Open Approach | Yes | 2026-04-01 |
| 0DDU4ZZ | Extraction of Omentum, Percutaneous Endoscopic Approach | Yes | 2026-04-01 |
| 0DDV0ZZ | Extraction of Mesentery, Open Approach | Yes | 2026-04-01 |
| 0DDV4ZZ | Extraction of Mesentery, Percutaneous Endoscopic Approach | Yes | 2026-04-01 |
| X2H43MC | Insertion of Temporary Intraluminal Device, Venous Angle Decompression using Impeller Pump into Left Innominate Vein, Percutaneous Approach, New Technology Group 12 | Yes | 2026-10-01 |
Grouper logic (v44 Definitions Manual)
The manual's split table for Lymphoma and Leukemia with Major O.R. Procedures gives one row per combination of criteria and the MS-DRG it assigns. DRG 821 is the row where MCC is No, CC is Yes.
Principal Diagnosis: 552 ICD-10-CM codes in this DRG's assignment logic; the first 12 are shown.
| ICD-10-CM code | Description |
|---|---|
| C26.1 | Malignant neoplasm of spleen |
| C46.3 | Kaposi's sarcoma of lymph nodes |
| C77.0 | Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck |
| C77.1 | Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes |
| C77.2 | Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes |
| C77.3 | Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes |
| C77.4 | Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes |
| C77.5 | Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes |
| C77.8 | Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions |
| C77.9 | Secondary and unspecified malignant neoplasm of lymph node, unspecified |
| C7B.01 | Secondary carcinoid tumors of distant lymph nodes |
| C81.00 | Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site |
Operating Room Procedures: 4536 ICD-10-PCS codes in this DRG's assignment logic; the first 12 are shown.
| ICD-10-PCS code | Description |
|---|---|
| 0016070 | Bypass Cerebral Ventricle to Nasopharynx with Autologous Tissue Substitute, Open Approach |
| 0016071 | Bypass Cerebral Ventricle to Mastoid Sinus with Autologous Tissue Substitute, Open Approach |
| 0016072 | Bypass Cerebral Ventricle to Atrium with Autologous Tissue Substitute, Open Approach |
| 0016073 | Bypass Cerebral Ventricle to Blood Vessel with Autologous Tissue Substitute, Open Approach |
| 0016074 | Bypass Cerebral Ventricle to Pleural Cavity with Autologous Tissue Substitute, Open Approach |
| 0016075 | Bypass Cerebral Ventricle to Intestine with Autologous Tissue Substitute, Open Approach |
| 0016076 | Bypass Cerebral Ventricle to Peritoneal Cavity with Autologous Tissue Substitute, Open Approach |
| 0016077 | Bypass Cerebral Ventricle to Urinary Tract with Autologous Tissue Substitute, Open Approach |
| 0016078 | Bypass Cerebral Ventricle to Bone Marrow with Autologous Tissue Substitute, Open Approach |
| 001607A | Bypass Cerebral Ventricle to Subgaleal Space with Autologous Tissue Substitute, Open Approach |
| 001607B | Bypass Cerebral Ventricle to Cerebral Cisterns with Autologous Tissue Substitute, Open Approach |
| 00160J0 | Bypass Cerebral Ventricle to Nasopharynx with Synthetic Substitute, Open Approach |
Code editor, HAC and CC/MCC exclusion notes for DRG 821
48 procedure codes in this DRG's logic are on the procedure list of HAC 11 (Surgical Site Infection - Bariatric Surgery), for example 0D16079. When the condition that category tracks is coded as a secondary diagnosis with a present-on-admission indicator of N or U after one of these procedures, the grouper does not count it as a CC or MCC. The FY2027 HAC list gives the diagnoses and procedures of each category.
The Definitions Manual lists the diagnosis and procedure codes that lead to DRG 821; these are the ones that are also on a Medicare Code Editor list and can draw that edit.
| MCE edit | List | Codes | Examples |
|---|---|---|---|
| Edit 4 | age conflict: pediatric diagnosis (age 0 to 17) | 3 | C93.30, C93.31, C93.32 |
| Edit 4 | age conflict: adult diagnosis (age 15 to 124) | 3 | C91.50, C91.51, C91.52 |
| Edit 6 | manifestation code, not allowed as principal diagnosis | 1 | D75.81 |
| Edit 11 | leukemia that makes autologous marrow or stem cell transfusion non-covered | 11 | C91.00, C92.00, C92.10 |
Documentation and denial exposure
As a surgical DRG, assignment depends on a qualifying operating-room procedure being coded from the operative report; a missing or non-OR procedure code drops the stay into a medical DRG in MDC 17 with a lower weight. The inpatient claim reports that procedure in ICD-10-PCS, which NCCI does not edit; the surgeon's professional claim for the same operation carries CPT and HCPCS codes, and the NCCI pair checker for those professional codes shows whether two of them bundle. Because this family splits by severity, auditors target CC and MCC capture: each secondary diagnosis must be documented as present, monitored, evaluated or treated during the stay to survive a DRG-validation review. Typical inpatient denial codes for this group: CARC 16 (claim lacks information needed to group the stay), CARC 50 (the admission or procedure is judged not medically necessary), CARC 97 (a service is bundled into the DRG payment).
For teams evaluating QuickIntell software
Evaluate a documentation and coding workflow for DRG 821
Explore QuickCode for qualified coder review and documentation clarification, or QuickScribe for clinician-reviewed visit documentation. Confirm inpatient scope, the supported grouper version and reviewer responsibilities during evaluation. This public reference is not a production grouper and does not determine a claim's reimbursement.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — DRG 821
What is MS-DRG 821?
MS-DRG 821 is "Lymphoma and Leukemia with Major O.R. Procedures with CC", a surgical Medicare Severity Diagnosis-Related Group in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms). Medicare pays inpatient stays grouped here at the hospital's base rate multiplied by the DRG relative weight.
What is the FY2027 relative weight for DRG 821?
The FY2027 relative weight is 2.2023 (IPPS final rule Table 5, effective October 1, 2026). In FY2026 it was 2.2386, a change of -1.6%.
What is the Medicare base payment for MS-DRG 821?
$15,081.35 for operating costs plus $1,189.13 for capital, $16,270.48 together, at the FY2027 national rates: weight 2.2023 times the $6,848.00 operating standardized amount and the $539.95 capital rate (IPPS Tables 1A and 1D as corrected by CMS-1849-CN3). DRG 820 (with MCC) comes to $42,786.99 operating on the same basis. DRG 822 (without CC/MCC) comes to $7,719.07 operating on the same basis. The hospital's wage index, IME, DSH, outlier and transfer adjustments change what a given stay is paid.
What is the average length of stay for DRG 821?
CMS reports a geometric mean length of stay of 3.1 days and an arithmetic mean of 4.9 days for FY2027. The geometric mean is used for transfer-payment calculations.
Which DRGs are in the same CC/MCC family as 821?
DRG 820 (with MCC, weight 6.2481, GMLOS 11.2 days); DRG 822 (without CC/MCC, weight 1.1272, GMLOS 1.4 days). Together with DRG 821 the family spans 1.1272 to 6.2481, a 5.54x spread, so documented complications and comorbidities change payment materially.
What documentation supports the severity level of DRG 821?
DRG 821 is reached when the stay carries a secondary diagnosis from the CMS Complication or Comorbidity list but none from the MCC list. Common CC captures include chronic kidney disease stage 3 and above, uncontrolled diabetes with manifestations, malnutrition of specified severity and heart failure of a stated type. Each must be documented by the treating clinician and show clinical relevance in the record; a condition listed only in the problem list without assessment is the most frequent reason a CC is removed on audit and the stay drops to the base DRG.
Which codes group to DRG 821?
The v44 Definitions Manual lists 552 principal diagnosis codes and 4,536 operating room procedures codes for this group. Examples from the principal diagnosis list, C77.2 (Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes); C77.3 (Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes); and from the operating room procedures list, 0016074 (Bypass Cerebral Ventricle to Pleural Cavity with Autologous Tissue Substitute, Open Approach); 0016075 (Bypass Cerebral Ventricle to Intestine with Autologous Tissue Substitute, Open Approach).
Is DRG 821 a post-acute transfer DRG?
No. DRG 821 is not on the FY2027 post-acute care transfer list, so the transfer per-diem policy does not apply to it.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- IPPS FY2027 Table 5 as corrected by correction notice CMS-1849-CN3Version v44 FY2027 (final rule + CN3) · effective 2026-10-01 · file CMS-1849-CN Table 5.txtSHA-256 2cc4e0b083e62e40…
- IPPS FY2026 Final Rule Table 5 (CMS-1833-F)Version v43 FY2026 · effective 2025-10-01 · file CMS-1833-F Table 5.txtSHA-256 bf8c390d14b3cd3e…
- ICD-10 MS-DRG Definitions Manual v44 (text)Version v44 · effective 2026-10-01 · file fy2027-fr-icd10-ms-drg-definitions-manual-files-v44.zipSHA-256 ae4f6c11727fe91f…
Disclaimer
This page is an operational reference compiled from the CMS IPPS FY2027 final rule (Table 5) and the v44 ICD-10 MS-DRG Definitions Manual. Relative weights are national factors; actual payment depends on each hospital's wage-adjusted base rate, add-ons, outliers and transfer adjustments. Nothing here is legal, clinical or billing advice; verify grouping against your encoder and the published CMS files.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.